The use of active surveillance and watchful waiting increased from 13.2 percent in 2010 to 53.8 percent in 2020 among patients with intermediate-risk prostate cancer, according to a recent study published in JAMA.
A new blood test may help reduce unnecessary prostate biopsies and can detect prostate cancer with similar sensitivity to standard screening in patients across racial and ethnic groups, according to a recent study published in the Journal of Clinical Oncology.
Northwestern Medicine investigators have discovered new molecular mechanisms underlying DNA repair dysregulation in cancer cells, findings that may inform the development of new targeted therapies for patients that have become resistant to standard treatments.
A new Northwestern Medicine study suggests using an alternative approach to prostate biopsy is as effective at detecting cancer as the current approach, but without the risk of infection or need for prophylactic antibiotics.
Immunotherapy administered before and after chemotherapy along with surgical removal of the bladder improved survival compared to chemotherapy alone in patients with muscle-invasive bladder cancer, according to a recent study published in the New England Journal of Medicine.
Investigators have discovered that aberrant activation of a specific oncoprotein drives key tumor promoting changes in the prostate tissue microenvironment during cancer progression, according to a Northwestern Medicine study published in Nature Communications.
RNA modifications could serve as a therapeutic target for certain types of cancer, according to a new study published in Molecular Cell which sheds new light on the complex process underlying RNA transcription.
Patients with immunotherapy-resistant bladder cancer who received a novel combination treatment demonstrated improved response to treatment, according to a recent study published in Nature Medicine.
A dysfunctional enzyme may lead to nonalcoholic fatty liver disease in mice, according to a study published in Science Advances.
Patients with metastatic urothelial cancer and increased expression of the NECTIN4 gene had a dramatically better response to antibody treatment than patients with reduced gene expression, according to recent findings published in the Journal of Clinical Oncology.